On Wednesday, CareDx reached an important technical milestone, with its Relative Strength (RS) Rating moving into the 90-plus percentile with an improvement to 92, a rise from 89 the day before.
Here Are 3 Keys For Successful Stock Investing
This proprietary rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the best-performing stocks often have an 80 or higher RS Rating at the beginning of a new price run.
CareDx has moved more than 5% past a 17.03 entry in a second-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
CareDx posted 0% EPS growth in the latest quarterly report, while sales growth came in at 32%. Look for the next report on or around Apr. 30.
CareDx holds the No. 14 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
